Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for avatrombopag

  1. Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating primary chronic immune thrombocytopenia in adults.

  2. Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA626)

    Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

  3. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)

    Evidence-based recommendations on lusutrombopag (Mulpleo) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

  4. Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]

    Discontinued [GID-TA10737]

  5. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  6. Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

    Discontinued [GID-TA10297]

  7. NICE begins phased restart of non-COVID-19 guidance

    NICE has begun a phased restart of publishing non-COVID-19 guidance as the NHS and wider health and care system start to return to normal arrangements.